
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …

ViiV Healthcare has secured its first global approval for its once-monthly treatment Cabenuva, it has emerged, to replace current antiretroviral …

